Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees

被引:30
作者
Bagarazzi, ML
Boyer, JD
Javadian, MA
Chattergoon, MA
Shah, AR
Cohen, AD
Bennett, MK
Ciccarelli, RB
Ugen, KE
Weiner, DB
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] MCP Hahnemann Univ, St Christophers Hosp Children, Dept Pediat, Philadelphia, PA USA
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[4] Wyeth Lederle Vaccines & Pediat, Malvern, PA USA
[5] Coulston Fdn, Alamogordo, NM USA
[6] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA
关键词
D O I
10.1086/314978
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
DNA vaccines encoding human immunodeficiency virus type 1 (HIV-1) env/rev and gag/pol were delivered intravaginally (IVAG) and intramuscularly (IM) to 2 pregnant chimpanzees. Vaccination was well tolerated and each chimpanzee developed antibodies (up to 1 year later) to both vaccines, Placental transfer of anti-Env and anti-Gag IgG was demonstrated in both maternal/infant pairs. Specific IgG was also demonstrated in saliva, vaginal, and rectal washes after IVAG immunization. Predominantly anti-HIV-1 IgA was detected in the milk of both mothers after both IM and IVAG immunization. Cellular responses included Gag-specific proliferation of lymphocytes and cytotoxic T lymphocytes against both antigens, These data suggest a strategy for induction of mucosal and systemic responses after both IM and IVAG delivery of DNA vaccines in a primate model and could ultimately be useful in lowering maternal-to-fetal transmission of HIV-1, perinatally and through breastfeeding.
引用
收藏
页码:1351 / 1355
页数:5
相关论文
共 15 条
[1]   Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees [J].
Bagarazzi, ML ;
Boyer, JD ;
Javadian, MA ;
Chattergoon, M ;
Dang, K ;
Kim, G ;
Shah, J ;
Wang, B ;
Weiner, DB .
JOURNAL OF MEDICAL PRIMATOLOGY, 1997, 26 (1-2) :27-33
[2]   DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees [J].
Boyer, JD ;
Ugen, KE ;
Chattergoon, M ;
Wang, B ;
Shah, A ;
Agadjanyan, M ;
Bagarazzi, ML ;
Javadian, A ;
Carrano, R ;
Coney, L ;
Williams, WV ;
Weiner, DB .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1501-1509
[3]   Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination [J].
Boyer, JD ;
Ugen, KE ;
Wang, B ;
Agadjanyan, M ;
Gilbert, L ;
Bagarazzi, ML ;
Chattergoon, M ;
Frost, P ;
Javadian, A ;
Williams, WV ;
Refaeli, Y ;
Ciccarelli, RB ;
McCallus, D ;
Coney, L ;
Weiner, DB .
NATURE MEDICINE, 1997, 3 (05) :526-532
[4]   Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus [J].
Girard, M ;
vanderRyst, E ;
BarreSinoussi, F ;
Nara, P ;
Tartaglia, J ;
Paoletti, E ;
Blondeau, C ;
Jennings, M ;
Verrier, F ;
Meignier, B ;
Fultz, PN .
VIROLOGY, 1997, 232 (01) :98-104
[5]   COMPARATIVE CLONAL ANALYSIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CD4+ AND CD8+ CYTOLYTIC LYMPHOCYTES-T ISOLATED FROM SERONEGATIVE HUMANS IMMUNIZED WITH CANDIDATE HIV-1 VACCINES [J].
HAMMOND, SA ;
BOLLINGER, RC ;
STANHOPE, PE ;
QUINN, TC ;
SCHWARTZ, D ;
CLEMENTS, ML ;
SILICIANO, RF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (06) :1531-1542
[6]  
Jansson M, 1997, ACTA PAEDIATR, V86, P39
[7]   Development of a multicomponent candidate vaccine for HIV-1 [J].
Kim, JJ ;
Ayyavoo, V ;
Bagarazzi, ML ;
Chattergoon, M ;
Boyer, JD ;
Wang, B ;
Weiner, BD .
VACCINE, 1997, 15 (08) :879-883
[8]   MUCOSAL IMMUNIZATION WITH A LIVE, VIRULENCE-ATTENUATED SIMIAN IMMUNODEFICIENCY VIRUS (SIV) VACCINE ELICITS ANTIVIRAL CYTOTOXIC T-LYMPHOCYTES AND ANTIBODIES IN RHESUS MACAQUES [J].
LOHMAN, BL ;
MCCHESNEY, MB ;
MILLER, CJ ;
OTSYULA, M ;
BERARDI, CJ ;
MARTHAS, ML .
JOURNAL OF MEDICAL PRIMATOLOGY, 1994, 23 (2-3) :95-101
[9]   Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization [J].
Lubeck, MD ;
Natuk, R ;
Myagkikh, M ;
Kalyan, N ;
Aldrich, K ;
Sinangil, F ;
Alipanah, S ;
Murthy, SCS ;
Chanda, PK ;
Nigida, SM ;
Markham, PD ;
ZollaPazner, S ;
Steimer, K ;
Wade, M ;
Reitz, MS ;
Arthur, LO ;
Mizutani, S ;
Davis, A ;
Hung, PP ;
Gallo, RC ;
Eichberg, J ;
RobertGuroff, M .
NATURE MEDICINE, 1997, 3 (06) :651-658
[10]   First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response [J].
MacGregor, RR ;
Boyer, JD ;
Ugen, KE ;
Lacy, KE ;
Gluckman, SJ ;
Bagarazzi, ML ;
Chattergoon, MA ;
Baine, Y ;
Higgins, TJ ;
Ciccarelli, RB ;
Coney, LR ;
Ginsberg, RS ;
Weiner, DB .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (01) :92-100